Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions
Molecular Biology Reports · 2026-12 · 53 (1)
DOI: 10.1007/s11033-026-12017-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, online erschienen am 26.05.2026. Verfasst von Aysima Önal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering and Natural Sciences, Department of Molecular Biology and Genetics, İstinye University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering and Natural Sciences, Department of Molecular Biology and Genetics, İstinye University, Istanbul, Turkey.
- Faculty of Engineering and Natural Sciences, Department of Molecular Biology and Genetics, İstinye University, Istanbul, Turkey. furkan1988ayaz@gmail.com.
- Odessa Medical School, Department of Medical Biology and Chemistry, Odessa, Ukraine. furkan1988ayaz@gmail.com.
- Faculty of Engineering and Natural Sciences, Department of Biomedical Engineering, İstinye University, Istanbul, Turkey. esra.aydemir81@gmail.com.
Zitieren
APA
Önal, A., Ayaz, F., & Aydemir, E. (2026). Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions. Molecular Biology Reports, 53(1). https://doi.org/10.1007/s11033-026-12017-0
Vancouver
Önal A, Ayaz F, Aydemir E. Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions. Molecular Biology Reports. 2026;53(1). doi:10.1007/s11033-026-12017-0
BibTeX
@article{nal2026,
author = {Önal, Aysima and Ayaz, Furkan and Aydemir, Esra},
title = {Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions},
journal = {Molecular Biology Reports},
year = {2026},
volume = {53},
number = {1},
doi = {10.1007/s11033-026-12017-0}
}
EUVIMED